Alpha MSH in Ocular Disease

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-06

Study Completion Date

2021-10-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease. Alpha MSH has been shown to have an important role in the regulation of ocular immunity in animal models of inflammatory retinal diseases and retinal dystrophies, and there may be a protective effect of alpha MSH. By studying the levels of alpha MSH in your eye we may better understand its role in advanced dry macular degeneration. By studying the levels of this molecule we hope to better understand if it may be a good target for future treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study

NCT05045703

Choroideremia

WITHDRAWN NA

Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy

NCT00060749

Macular Degeneration

COMPLETED PHASE1

Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa

NCT00004827

Retinitis Pigmentosa

COMPLETED NA

Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A

NCT00000116

Retinitis Pigmentosa

COMPLETED PHASE3

Natural History Study in Patients with PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa

NCT06323772

Retinitis Pigmentosa

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A small amount (0.1 mL) of aqueous humor would be removed from the study eye in the clinic setting. This sample will be processed and then sent off for measurement of alpha MSH levels.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Dry Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Advanced Dry macular degeneration

Group Type OTHER

Alpha MSH assay

Intervention Type DEVICE

Assay to detect levels of alpha MSH in intraocular fluid.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alpha MSH assay

Assay to detect levels of alpha MSH in intraocular fluid.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 60 years or older
* diagnosis of advanced dry macular degeneration with foveal geographic atrophy
* limited vision or blindness (20/100 or worse) in that eye
* pseudophakia (prior cataract surgery in that eye)

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes